Purpose Comorbid medical conditions are common among breast cancer survivors, contribute to poorer long-term survival and increased overall mortality, and may be ameliorated by weight loss. This secondary analysis evaluated the impact of a weight loss intervention on comorbid medical conditions immediately following an intervention (12 months) and 1-year postintervention (24 months) using data from the Exercise and Nutrition to Enhance Recovery and Good health for You (ENERGY) trial-a phase III trial which was aimed at and successfully promoted weight loss. Methods ENERGY randomized 692 overweight/obese women who had completed treatment for early stage breast cancer to either a 1-year group-based behavioral intervention designed to achieve and maintain weight loss or to a less intensive control intervention. Minimal support was provided postintervention. New medical conditions, medical conditions in which non-cancer medications were prescribed, hospitalizations, and emergency room visits, were compared at baseline, year 1, and year 2. Changes over time were analyzed using chi-squared tests, Kaplan-Meier, and logistic regression analyses. Results At 12 months, women randomized to the intervention had fewer new medical conditions compared to the control group (19.6 vs. 32.2 %, p < 0.001); however, by 24 months, there was no longer a significant difference. No difference was observed in each of the four conditions for which non-cancer medications were prescribed, hospital visits, or emergency visits at either 12 or 24 months. Conclusions These results support a short-term benefit of modest weight loss on the likelihood of comorbid conditions; however, recidivism and weight regain likely explain no benefit at 1-year postintervention follow-up.
Introduction
Early detection and effective initial treatments have led to a growing population of breast cancer survivors, with ∼3.7
Electronic supplementary material The online version of this article (doi:10.1007/s00520-016-3141-2) contains supplementary material, which is available to authorized users. million women in the USA living with a history of breast cancer [1] . In addition to their cancer diagnosis, more than 40 % of breast cancer survivors present with another chronic comorbid health condition at the time of their cancer diagnosis or shortly after diagnosis [2] [3] [4] , and the development of new conditions postdiagnosis is common [5, 6] . These comorbid medical conditions contribute to poorer long-term survival and increased overall mortality [2-4, 7, 8] . Among breast cancer survivors, there is great concern about recurrence of their cancer, but women over age 65 years are more likely to die of cardiovascular disease than from their breast cancer diagnosis [9] . Moreover, an increasing number of comorbid conditions are associated with poorer physical and mental quality of life among women with a previous diagnosis of breast cancer [10] . Determining effective ways to prevent the development of new chronic conditions among breast cancer survivors is imperative.
Overweight and obesity, as well as physical inactivity, are significant predictors for developing comorbidities among cancer survivors [5] , as excess adiposity contributes to the development of medical conditions such as type 2 diabetes, hypertension, dyslipidemia, coronary heart disease, heart failure, obstructive sleep apnea, gastroesophageal reflux, and osteoarthritis [11] . In the USA, approximately 70 % of women diagnosed with breast cancer are overweight or obese at the time of their diagnosis [12] . This high prevalence is due in part to obesity being a major risk factor for postmenopausal estrogen-dependent breast cancer [13] . Once diagnosed, obesity increases the risk of overall mortality and breast cancerspecific mortality, which includes deaths caused by recurrence or a second primary breast cancer, in both premenopausal and postmenopausal women [14] . Weight gain following breast cancer diagnosis is common [15] and contributes to increased cancer-related symptoms and worse health-related quality of life [16] [17] [18] [19] .
Evidence in non-cancer patients suggests that weight loss and physical activity can prevent diabetes [20, 21] , improve diabetes management, blood pressure, and cardiovascular disease risk profiles [22, 23] and lead to fewer hospitalizations, less medication use, and lower costs [24, 25] . No studies to date, however, have evaluated the effect of weight loss on comorbid health conditions among breast cancer survivors.
The Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) trial was a multicenter phase III randomized controlled trial of a 1-year behavioral weight loss intervention followed by an observational year postintervention follow up that previously reported a significant reduction in weight associated with the intervention at 12 (−6 versus −1.5 %, p < 0.001) and 24 months (−3.7 versus −1.3 %, p < 0.001), as well as significant decreases in both systolic and diastolic blood pressure at these time points [26] . The purpose of this secondary analysis was to evaluate the effect of the weight loss intervention on self-reported comorbidities as indicated by hospitalizations, emergency room (ER) visits, new medical conditions, and medical conditions for which medication was prescribed at the end of the intervention period and then follow-up at 1 year postintervention.
Methods

Study design
The ENERGY trial was a multicentered phase III randomized controlled trial of a 1-year behavioral group-based weight loss program with telephone counseling and tailored newsletters with the primary aim to achieve and maintain at least a 7 % initial body weight loss after 2 years among overweight/obese breast cancer survivors. The overall focus of the intervention was to increase physical activity and decrease energy intake. Details of the design, intervention, and study procedures have been published previously [26, 27] . All study procedures were approved by the institutional review boards of each site and participants provided written informed consent.
Study population
From 2010 to 2012, 692 women with a previous diagnosis of invasive breast cancer were recruited and enrolled from four clinical sites (San Diego, CA; Denver, CO; St. Louis, MO; and Birmingham, AL). Women who were ≥21 years of age with a diagnosis of breast cancer (stages I (≥1 cm), II, or III) within the previous 5 years who had completed all initial therapies except endocrine therapy, had a body mass index (BMI) 25-45 kg/m 2 , and were able to comply with study procedures were included in this trial. Women were excluded if they had a history of malignancies other than initial breast cancer diagnosis or non-melanoma skin cancer, serious psychiatric illness, and any medical condition substantially limiting moderate physical activity. Participants were randomized with equal distribution to either the intervention or control arm and were blocked on age (older/younger than 55 years), breast cancer stage (I vs. II and III), and study site. The consort diagram is presented in Fig. 1 .
Interventions
Specific details of the weight loss intervention aimed at increasing physical activity and decreasing energy intake have been reported previously [27] . Briefly, the intervention was based on the behavioral determinants model [28] which is constructed on the social cognitive theory [29] [30] [31] . Based on this theory, active goal setting of weight, dietary intake, and physical activity was encouraged; successes of short-term goals contributed to increased self-efficacy which was instrumental in participants obtaining their weight goals. The intervention was designed as a 12-month intervention and follow-up 1 year later. Participants randomized to the intervention group participated in weekly 1-h closed group sessions for 4 months followed by sessions every other week for 2 months. Groups consisted of an average of 15 participants and were led by 1-2 leaders with training in nutrition, psychology, and/or exercise physiology. Following the intensive phase of the intervention, the groups met monthly from 6 to 12 months. Brief personalized telephone and/or e-mail guidance was used to further reinforce and individualize the approaches discussed in the group sessions. From 6 to 24 months, additional support and reinforcement of selfmanagement was also provided through quarterly tailored print newsletters. The newsletters were tailored based on individually collected information about dietary intake, physical activity, and weight and included guidance to promote increased physical activity and regulation of dietary intake. Minimal weight loss support was provided in the second year of the study.
Participants randomized to the control group were provided an individualized weight loss counseling session at baseline and at 6 months. These sessions were based on standard resource materials that were available in the public domain and included weight management and current physical activity recommendations. During the first year of the trial, control group participants were invited to attend optional seminars on healthy living other than weight control every other month.
Measures
Current comorbidities were self-reported at baseline for 12 conditions (heart disease, high blood pressure, lung disease, diabetes, ulcers or stomach disease, kidney disease, liver disease, anemia or other blood disease, depression, osteoarthritis or degenerative arthritis, rheumatoid arthritis, and back pain) and text fields provided for other medical problems. Any new medical conditions or problems were assessed at the 6-, 12-, 18-, and 24-month follow-up clinic visits. Hospitalization that resulted in at least one overnight stay within the last year, emergency room visits within the last year, and medical conditions with concurrent prescription medications other than those for cancer treatment were assessed by self-report at baseline. New hospitalizations and emergency room visits, new medical conditions, and any changes to prescription medications were also reported at all follow-up clinic visits. Medical documentation was obtained for all hospitalizations, emergency room visits, and new cardiovascular events and cancers.
Trained staff measured height at baseline as well as weight at baseline and 6-, 12-, 18-, and 24-month follow-up clinic visits. Using the height and weight measures, BMI was calculated as weight in kilograms divided by height in meters squared (kg/m 2 ). Age, education, race, Hispanic ethnicity, smoking status, and menopausal status were reported on baseline questionnaires, whereas information on breast cancer diagnosis and treatments (including surgery and chemotherapy, and endocrine therapy) was abstracted from medical records.
Statistical analyses
The outcome measures for this evaluation were any new medical conditions, any hospital visits, any ER visits, and conditions in which non-cancer medications were prescribed with a specific focus on four leading categories of medications (antihypertensives, lipid-lowering agents, diabetes medications, and acid reflux medications). Of the 587 participants who provided weight data at 24 months, 516 had comorbidity measures at 12 months and 510 had comorbidity measures at 24 months.
Participant characteristics were evaluated to compare those women randomized to the intervention versus those in the control group using t tests for continuous variables and chisquared tests for categorical variables. Changes in comorbidity measures were analyzed using chi-squared tests for categorical outcomes (any new medical conditions, four leading conditions in which non-cancer medications were prescribed, any ER visits, or hospitalizations) at 12-and 24-month time periods. To further explore the association between any new medical conditions by study arm, a Kaplan-Meier survival curve was used to evaluate the time until the date of the first reported new medical condition. Censoring occurred at the last reported study visit if no new medical condition was reported. The log-rank test was used to assess statistically significant differences in the Kaplan-Meier survival curve. Additionally, logistic regression analysis was used to evaluate the association between any new medical conditions and changes in body weight at the 12-month time period and then 24-month time period adjusted for age and number of comorbid conditions at baseline. Statistical analyses were based on two-sided statistical tests with an alpha level of 0.05. Analyses were conducted using SAS version 9.4 (Cary, North Carolina).
Results
The majority of the participants in this study were collegeeducated, non-Hispanic white, non-smokers, who were postmenopausal, and had been diagnosed with estrogen receptorpositive breast cancer, stage I or II. There were no statistically significant differences in study characteristics at baseline by groups, including comorbid conditions ( Table 1 ). The predominant comorbid conditions at baseline were hypertension (33.1 % in the intervention group vs 31.6 % in the control group), depression (23.6 % in the intervention group vs 19.0 % in the control group), and osteoarthritis (7.6 % in the intervention group vs 7.8 % in the control group), as well as Bother^comorbidities among which thyroid disease was most commonly cited. The mean number of conditions for which participants were taking a non-cancer prescription medication was 2.3 at study entry. The mean number of comorbid conditions was 1.1 (SD 1.1). Overall, 34.7 % of women reported one comorbid condition, 17.2 % reported two conditions, and 11.6 % reported three or more conditions at baseline. The overall completion of the study was 85 % [26] , and women who did not complete the 24-month study visit (n = 105) had the same number of mean baseline comorbid conditions, i.e., 1.1 (SD 1.1), as compared to women who completed the study.
At 12 months, there were significantly fewer interventions than control participants who reported new medical conditions (19.6 vs. 32.2 %, p < 0.001); however, by the 24-month time point, there was no longer a significant difference between the groups (Table 2) . A summary of the disease categories for new conditions is reported in the supplemental table. There was no difference between the intervention and control groups in conditions for which non-cancer medications were prescribed, hospital visits, or ER visits at either the 12-or 24-month follow-up time points.
The Kaplan-Meier curve showed separation between the groups beginning at 6 months with the largest difference around 12 months (p = 0.04) followed by a decrease during the second year (p = 0.41, Fig. 2) . Additionally, when logistic regression analysis of any new comorbid conditions at 12 months by weight change was conducted, fewer new medical conditions were associated with weight loss after adjustment (p = 0.04).
Discussion
Following breast cancer diagnosis, healthy weight management is an essential component of self-care strategies to prevent health outcomes such as recurrence, secondary primary cancers, and risk for other chronic diseases [32] . The ENERGY trial is the largest randomized controlled trial of a behavioral weight loss intervention conducted to date among Findings from this trial demonstrate that the weight loss intervention, which promoted modest weight loss, had an impact in the short-term rates of new medical conditions. In addition, there were no betweengroup differences in the four medical conditions for which non-cancer medications were prescribed, hospitalizations, or emergency room visits. Intentional weight loss is an effective strategy for improving obesity-associated comorbidities and reducing the development of new medical conditions in non-cancer adult populations [23] [24] [25] [33] [34] [35] . Surgical methods of weight loss result in larger weight loss, better weight maintenance, and improved comorbidities as compared to weight loss achieved through lifestyle changes; however, adverse events have been noted with surgery and not everyone will qualify for the surgical option [33, 36] . Within the ENERGY trial, the largest weight loss (−6.0 % in the intervention group vs. −1.5 % in the control group) that was observed occurred during the first year of the intervention when the active weight loss phase was being implemented, and this corresponds to the significant finding of lower comorbidities among the intervention group. Furthermore, fewer comorbid conditions were reported at the 12-month time point with weight loss. Noteworthy, there were differences in new cardiovascular conditions at the 12-month time point; three (1.1 %) in the intervention versus eight (3.2 %) in the control group. In the second year of the trial, support was minimal and weight was regained. Although a mediation model was beyond the scope of this analysis, the independent association of weight change with both the intervention [26] and comorbid conditions at both 12 and 24 months mirrors what was observed for the intervention and suggests that the intervention influences new comorbid conditions primarily through weight changes. In the general population of overweight and obese adults, clinical guidelines recommend initial weight loss of 5-10 % for health benefits [37] ; weight loss of this magnitude (6 %) was observed immediately following the 1-year intervention.
Findings from this study reinforce the need for continued support of weight loss maintenance to prevent weight regain and subsequent comorbidities. Within the ENERGY trial, 55 % of the intervention group had lost 5 % or more of their initial weight; however, this decreased to 44 % by 24 months [26] . Weight regain is common after weight loss; a systematic review suggests that on average, 50 % of weight loss is regained at 1 year [38] . Interventions that can extend treatment and support periods as well as incorporate successful strategies such as continued self-monitoring, increased physical activity, and regular meal planning along with cognitive restructuring to mitigate responses to lapses [39] [40] [41] will be more effective in maintaining weight loss and reducing the development of obesity-related diseases.
Excess adiposity contributes to the prevalence of comorbid conditions among survivors as well as to the development of new comorbid conditions [4, 5] . Although comorbid conditions are common among women with a previous diagnosis of breast cancer ranging from 42 to 54 % [2] [3] [4] , 63.5 % of ENERGY participants reported at least one comorbidity at study entry. This somewhat higher prevalence of comorbidities at baseline is likely attributable to the targeted enrollment of overweight and obese breast cancer survivors, which has been previously shown to result in higher Charlson comorbidity index scores among breast cancer survivors [4] .
As with all population-based research, this trial had limitations that need to be considered when interpreting these findings. Overall completion of the study was high (85 %) [26] and there was no difference in mean number of baseline comorbidities between women who did versus those who did not complete the 24-month study visit. Nevertheless, this study recruited primarily educated, non-Hispanic white women with early stage breast cancer who were overweight or obese; thus, these findings can only be generalized to this population. Due to a limited number of racial and ethnic minorities in the current trial, possible difference by race and ethnicity could not be fully evaluated. Medications and changes to medications were self-reported; however, the dosages of medications were not collected and thus, we were unable to evaluate any possible changes in the dosage of medications associated with the intervention. Finally, the data on new medical conditions were self-reported followed by medical record confirmation for cardiovascular disease and new cancers.
In conclusion, modest weight loss demonstrated in the ENERGY behavioral weight loss intervention reduced incident comorbidities following an intensive weight loss intervention. These results support the effort to prescribe and encourage healthy weight management efforts for overweight and obese breast cancer survivors and highlight the need to provide continued support so that weight loss and health benefits are maintained in the long term.
